Why the study?
Endothelial dysfunction in cardiovascular disease is driven by oxidative stress, inflammation, and platelet activation, and whether rivaroxaban alone or combined with clopidogrel could counteract platelet-induced oxidative endothelial injury and preserve endothelial function was investigated.
Population
Patients on chronic antiplatelet therapy initiating rivaroxaban, plus in vitro human endothelial cell and ex vivo mouse models
Comparison
Before vs after rivaroxaban initiation in patients; rivaroxaban alone or with clopidogrel in experimental models
Design
Prospective multicenter cohort clinical study with parallel in vitro and ex vivo experiments
Answers are grounded in this paper and cite their sources.
BACKGROUND: Endothelial dysfunction is a hallmark of cardiovascular disease, driven by oxidative stress, inflammation, and platelet activation. We hypothesized that the FXa inhibitor rivaroxaban, alone or combined with clopidogrel, could counteract platelet-induced oxidative injury to the endothelium and preserve endothelial function. METHODS: We conducted a prospective multicenter cohort clinical study in patients on chronic antiplatelet therapy (mostly aspirin) who initiated rivaroxaban, measuring indices of oxidative stress, endothelial function (nitric oxide bioavailability, ICAM-1/VCAM-1 levels), and platelet activation before and after rivaroxaban. In parallel, human endothelial cells were exposed to convulxin-activated platelet supernatants from healthy donors with or without rivaroxaban±clopidogrel, and assessed for NOX2 expression/activity, adhesion molecules, nitric oxide (NO) production, and tube-forming capacity. An ex vivo mouse model of angiotensin II-induced endothelial dysfunction was used to evaluate vascular relaxation responses after incubation with rivaroxaban and/or clopidogrel. RESULTS: production, downregulated endothelial NOX2 expression and sNOX2-dp release, and restored angiogenic capacity in endothelial cells exposed to activated platelets. Clopidogrel alone had negligible effects on these parameters. Notably, adding clopidogrel to rivaroxaban provided no additional endothelial benefit beyond rivaroxaban monotherapy. In an ex vivo hypertensive vessel model, rivaroxaban (but not clopidogrel) markedly improved endothelium-dependent relaxation. CONCLUSIONS: Rivaroxaban effectively preserves endothelial function by inhibiting platelet-induced NOX2-mediated oxidative stress and inflammation. The lack of any additive benefit from clopidogrel suggests that rivaroxaban alone may be mechanistically sufficient to counteract platelet-driven endothelial dysfunction. These findings reveal a novel vasoprotective mechanism for rivaroxaban and underscore its potential clinical value in mitigating vascular injury beyond its established antithrombotic effects.
No takes yet. Share an insight, caveat, or question.
D’Amico et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: